Sarepta Therapeutics Inc. (SRPT)
NASDAQ: SRPTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
SRPT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.85B
- Forward P/E
- 7.26
- EPS (TTM)
- -$1.57
- Dividend yield
- None
- 52-week range
- 14.68 – 25.32
- Day range
- 16.98 – 17.65
- Volume / Avg
- 2.87M / 2.99M
- Beta
- —
- Shares outstanding
- 105.63M
- Next earnings
- Nov 2, 2026
52-week range
SRPT stock today
Shares of Sarepta Therapeutics (SRPT) finished higher on Oct 7 at $17.50, a gain of 1.10% or $0.19 per share, versus the S&P 500's 0.22% decline. Shares are 30.9% below their 52-week high of $25.32, set on Oct 8, 2025 and 19.2% above the 52-week low of $14.68, in the middle of the past year's range. SRPT is down 18.7% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 24.3%.
Sarepta Therapeutics has posted a net loss over the last twelve months (EPS of -$1.57), so its P/E ratio is not meaningful. Sarepta Therapeutics's next earnings report is expected on Nov 2, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Sarepta Therapeutics
Company profileSarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Michael E. Severino M.D.
- Headquarters
- Cambridge, MA
- Employees
- 835
- Website
- sarepta.com
Analyst forecast
ForecastConsensus (24 analysts)
hold
Avg. price target
$21.73+24.17%
- Strong buy 0
- Buy 7
- Hold 12
- Sell 3
- Strong sell 2
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 2, 2026
- EPS estimate
- $0.17
Sarepta Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ZBIOZenas BioPharma Inc. | 28.18 | +4.60% | $1.84B | vs SRPT |
| XERSXeris Biopharma Holdings Inc. | 10.11 | +0.40% | $1.84B | vs SRPT |
| ADRXADARx Pharmaceuticals Inc. | 17.33 | -6.73% | $1.85B | vs SRPT |
| XNCRXencor Inc. | 24.26 | -0.41% | $1.80B | vs SRPT |
| BHVNBiohaven Ltd. | 11.88 | -1.66% | $1.79B | vs SRPT |
| TRVITrevi Therapeutics Inc. | 13.14 | -0.30% | $1.87B | vs SRPT |
| PVLAPalvella Therapeutics Inc. | 130.59 | +2.02% | $1.88B | vs SRPT |
| AGIOAgios Pharmaceuticals Inc. | 31.79 | +0.22% | $1.90B | vs SRPT |
Indexes, lists and sector
Sarepta Therapeutics stock FAQ
What is Sarepta Therapeutics's stock price today?
SRPT last traded at $17.50 as of Oct 7, 4:00 PM EDT, up 1.10% on the day. Prices are delayed at least 15 minutes.
Does Sarepta Therapeutics pay a dividend?
No. Sarepta Therapeutics does not currently pay a regular cash dividend.
When is Sarepta Therapeutics's next earnings date?
Sarepta Therapeutics is expected to report earnings on Monday, November 2, 2026. Analysts expect EPS of $0.17.
Who is Sarepta Therapeutics's CEO?
Dr. Michael E. Severino M.D. is the chief executive officer of Sarepta Therapeutics Inc., which has about 835 employees.
Has SRPT ever split its stock?
Yes. The most recent SRPT stock split was a 1-for-6 split on Jul 12, 2012.
What is the SRPT 52-week high?
The 52-week high for SRPT is $25.32 and the 52-week low is $14.68. The stock is currently 30.9% below its high.